Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 656 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2015', provides an overview of the Diffuse Large B-Cell Lymphoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diffuse Large B-Cell Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Diffuse Large B-Cell Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Diffuse Large B-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Diffuse Large B-Cell Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Diffuse Large B-Cell Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Diffuse Large B-Cell Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 11
Global Markets Direct Report Coverage 11
Diffuse Large B-Cell Lymphoma Overview 12
Therapeutics Development 13
Pipeline Products for Diffuse Large B-Cell Lymphoma - Overview 13
Pipeline Products for Diffuse Large B-Cell Lymphoma - Comparative Analysis 14
Diffuse Large B-Cell Lymphoma - Therapeutics under Development by Companies 15
Diffuse Large B-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes 22
Diffuse Large B-Cell Lymphoma - Pipeline Products Glance 23
Late Stage Products 23
Clinical Stage Products 24
Early Stage Products 25
Diffuse Large B-Cell Lymphoma - Products under Development by Companies 26
Diffuse Large B-Cell Lymphoma - Products under Investigation by Universities/Institutes 34
Diffuse Large B-Cell Lymphoma - Companies Involved in Therapeutics Development 35
AbbVie Inc. 35
Acetylon Pharmaceuticals, Inc. 36
Affimed Therapeutics AG 37
Amgen Inc. 38
Aprogen, Inc. 39
Arrien Pharmaceuticals, LLC 40
Astellas Pharma Inc. 41
AstraZeneca Plc 42
Aurigene Discovery Technologies Limited 43
Bayer AG 44
BeiGene(Beijing) Co.,Ltd 45
BIND Therapeutics, Inc. 46
Biocon Limited 47
Bristol-Myers Squibb Company 48
Celgene Corporation 49
Cell>Point, L.L.C. 50
Cellular Biomedicine Group, Inc. 51
Constellation Pharmaceuticals, Inc. 52
CTI BioPharma Corp. 53
Curis, Inc. 54
Cyclacel Pharmaceuticals, Inc. 55
Eisai Co., Ltd. 56
EpiZyme, Inc. 57
Erytech Pharma SA 58
F. Hoffmann-La Roche Ltd. 59
Genentech, Inc. 60
Gilead Sciences, Inc. 61
GlaxoSmithKline Plc 62
Hutchison MediPharma Limited 63
Idera Pharmaceuticals, Inc. 64
ImmunoGen, Inc. 65
Immunomedics, Inc. 66
Immunovaccine, Inc. 67
Incyte Corporation 68
Inflection Biosciences Limited 69
Johnson & Johnson 70
Juno Therapeutics Inc. 71
Karus Therapeutics Limited 72
Karyopharm Therapeutics, Inc. 73
Kite Pharma, Inc. 74
Mabion SA 75
mAbxience S.A. 76
MedImmune, LLC 77
Medivation, Inc. 78
Merck & Co., Inc. 79
Millennium Pharmaceuticals, Inc. 80
Mirati Therapeutics Inc. 81
Mirna Therapeutics, Inc. 82
Molplex Ltd. 83
MorphoSys AG 84
Neumedicines Inc. 85
Nimbus Therapeutics, LLC 86
Nordic Nanovector ASA 87
Novartis AG 88
Ono Pharmaceutical Co., Ltd. 89
Onyx Pharmaceuticals, Inc. 90
Pfizer Inc. 91
Philogen S.p.A. 92
Portola Pharmaceuticals, Inc. 93
ProNAi Therapeutics, Inc. 94
RedHill Biopharma Ltd. 95
Redx Pharma Plc 96
Respiratorius AB 97
Rhizen Pharmaceuticals S.A. 98
Sandoz International GmbH 99
Seattle Genetics, Inc. 100
Selvita SA 101
Taiho Pharmaceutical Co., Ltd. 102
TG Therapeutics, Inc. 103
Diffuse Large B-Cell Lymphoma - Therapeutics Assessment 104
Assessment by Monotherapy Products 104
Assessment by Combination Products 105
Assessment by Target 106
Assessment by Mechanism of Action 111
Assessment by Route of Administration 115
Assessment by Molecule Type 117
Drug Profiles 119
187Re-EC-G - Drug Profile 119
ABC-294640 - Drug Profile 120
acalabrutinib - Drug Profile 123
acalisib - Drug Profile 126
ACY-775 - Drug Profile 127
AFM-11 - Drug Profile 129
AFM-13 - Drug Profile 130
alisertib - Drug Profile 131
ARN-3236 - Drug Profile 135
ARN-3261 - Drug Profile 136
ASN-002 - Drug Profile 137
asparaginase - Drug Profile 138
atezolizumab - Drug Profile 140
azacitidine - Drug Profile 144
AZD-2811 - Drug Profile 148
AZD-3965 - Drug Profile 149
AZD-9150 - Drug Profile 151
bendamustine hydrochloride - Drug Profile 152
Betalutin - Drug Profile 155
BGB-3111 - Drug Profile 157
blinatumomab - Drug Profile 158
BLyS-gel - Drug Profile 161
BMS-986016 - Drug Profile 162
bortezomib - Drug Profile 163
brentuximab vedotin - Drug Profile 169
buparlisib hydrochloride - Drug Profile 176
BVX-20 - Drug Profile 180
carfilzomib - Drug Profile 181
CBM-C19.1 - Drug Profile 185
CBM-C20.1 - Drug Profile 186
CC-122 - Drug Profile 188
CC-223 - Drug Profile 190
Cellular Immunotherapy for Oncology - Drug Profile 191
Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile 192
cerdulatinib - Drug Profile 193
coltuximab ravtansine - Drug Profile 195
copanlisib hydrochloride - Drug Profile 197
CPI-0610 - Drug Profile 201
CPI-169 - Drug Profile 202
CUDC-907 - Drug Profile 203
CYC-065 - Drug Profile 205
daratumumab - Drug Profile 206
Darleukin - Drug Profile 210
denintuzumab mafodotin - Drug Profile 212
DPX-Survivac - Drug Profile 213
E-7449 - Drug Profile 217
entospletinib - Drug Profile 218
epacadostat - Drug Profile 219
everolimus - Drug Profile 221
GS-5829 - Drug Profile 227
GSK-2816126 - Drug Profile 228
HMPL-523 - Drug Profile 229
IBL-301 - Drug Profile 230
ibrutinib - Drug Profile 232
idelalisib - Drug Profile 239
IGN-002 - Drug Profile 242
imexon - Drug Profile 243
IMGN-529 - Drug Profile 245
IMO-8400 - Drug Profile 247
inebilizumab - Drug Profile 249
inebilizumab + rituximab - Drug Profile 251
inotuzumab ozogamicin - Drug Profile 252
IT-901 - Drug Profile 254
ixazomib citrate - Drug Profile 255
JCAR-014 - Drug Profile 259
JNJ-64052781 - Drug Profile 260
KA-2237 - Drug Profile 261
KTEC-19 - Drug Profile 262
lenalidomide - Drug Profile 265
mitoxantrone hydrochloride - Drug Profile 270
MK-2206 - Drug Profile 271
MK-8628 - Drug Profile 274
mocetinostat - Drug Profile 276
Monoclonal Antibody Conjugated to Target CD22 for Hematological Cancers - Drug Profile 279
Monoclonal Antibody to Agonize CD40 for Diffuse Large B-Cell Lymphoma and Solid Tumors - Drug Profile 280
MOR-208 - Drug Profile 281
MRX-34 - Drug Profile 283
NBD Peptide - Drug Profile 285
ND-2110 - Drug Profile 287
ND-2158 - Drug Profile 289
nivolumab - Drug Profile 291
NMIL-121 - Drug Profile 299
obinutuzumab - Drug Profile 301
ONC-201 - Drug Profile 304
pecazine - Drug Profile 307
pembrolizumab - Drug Profile 308
pidilizumab - Drug Profile 317
pixantrone dimaleate - Drug Profile 319
PNT-2258 - Drug Profile 323
polatuzumab vedotin - Drug Profile 325
PRT-060318 - Drug Profile 327
Pt-EC-G - Drug Profile 328
rituximab biosimilar - Drug Profile 329
rituximab biosimilar - Drug Profile 330
rituximab biosimilar - Drug Profile 331
rituximab biosimilar - Drug Profile 333
rituximab biosimilar - Drug Profile 334
romidepsin - Drug Profile 335
RP-6530 - Drug Profile 338
ruxolitinib phosphate - Drug Profile 339
SEL-24B489 - Drug Profile 344
selinexor - Drug Profile 345
SGN-CD70A - Drug Profile 351
SH-7129 - Drug Profile 352
Small Molecule to Inhibit IRAK-4 for Cancer and Inflammation - Drug Profile 354
Small Molecules for Diffuse Large B Cell Lymphoma - Drug Profile 355
Small Molecules to Inhibit BTK for Cancer and Autoimmune disorders - Drug Profile 356
Small Molecules to Inhibit IRAK4 for Immunology and Oncology - Drug Profile 357
Small Molecules to Inhibit NF-kappa B for Diffuse Large B-Cell Lymphoma - Drug Profile 358
sotrastaurin acetate - Drug Profile 359
spebrutinib besylate - Drug Profile 361
Synthetic Peptide to Inhibit Bcl-6 for Diffuse Large B-Cell Lymphoma and Acute Lymphoblastic Leukemia - Drug Profile 363
Synthetic Peptides to Target RBCK1 for Diffuse Large B-cell Lymphoma - Drug Profile 364
TAK-659 - Drug Profile 365
TAS-5567 - Drug Profile 366
tazemetostat - Drug Profile 367
tisagenlecleucel-T - Drug Profile 369
ublituximab + TGR-1202 - Drug Profile 372
ulocuplumab - Drug Profile 373
urelumab - Drug Profile 375
valproate sodium - Drug Profile 377
venetoclax - Drug Profile 378
vorinostat - Drug Profile 382
yttrium Y 90 epratuzumab tetraxetan - Drug Profile 386
Diffuse Large B-Cell Lymphoma - Recent Pipeline Updates 387
Diffuse Large B-Cell Lymphoma - Dormant Projects 631
Diffuse Large B-Cell Lymphoma - Discontinued Products 634
Diffuse Large B-Cell Lymphoma - Product Development Milestones 636
Featured News & Press Releases 636
Appendix 647
Methodology 647
Coverage 647
Secondary Research 647
Primary Research 647
Expert Panel Validation 647
Contact Us 647
Disclaimer 648

List of Tables

Number of Products under Development for Diffuse Large B-Cell Lymphoma, H2 2015 21
Number of Products under Development for Diffuse Large B-Cell Lymphoma - Comparative Analysis, H2 2015 22
Number of Products under Development by Companies, H2 2015 24
Number of Products under Development by Companies, H2 2015 (Contd..1) 25
Number of Products under Development by Companies, H2 2015 (Contd..2) 26
Number of Products under Development by Companies, H2 2015 (Contd..3) 27
Number of Products under Development by Companies, H2 2015 (Contd..4) 28
Number of Products under Development by Companies, H2 2015 (Contd..5) 29
Number of Products under Investigation by Universities/Institutes, H2 2015 30
Comparative Analysis by Late Stage Development, H2 2015 31
Comparative Analysis by Clinical Stage Development, H2 2015 32
Comparative Analysis by Early Stage Development, H2 2015 33
Products under Development by Companies, H2 2015 34
Products under Development by Companies, H2 2015 (Contd..1) 35
Products under Development by Companies, H2 2015 (Contd..2) 36
Products under Development by Companies, H2 2015 (Contd..3) 37
Products under Development by Companies, H2 2015 (Contd..4) 38
Products under Development by Companies, H2 2015 (Contd..5) 39
Products under Development by Companies, H2 2015 (Contd..6) 40
Products under Development by Companies, H2 2015 (Contd..7) 41
Products under Investigation by Universities/Institutes, H2 2015 42
Diffuse Large B-Cell Lymphoma - Pipeline by AbbVie Inc., H2 2015 43
Diffuse Large B-Cell Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2015 44
Diffuse Large B-Cell Lymphoma - Pipeline by Affimed Therapeutics AG, H2 2015 45
Diffuse Large B-Cell Lymphoma - Pipeline by Amgen Inc., H2 2015 46
Diffuse Large B-Cell Lymphoma - Pipeline by Aprogen, Inc., H2 2015 47
Diffuse Large B-Cell Lymphoma - Pipeline by Arrien Pharmaceuticals, LLC, H2 2015 48
Diffuse Large B-Cell Lymphoma - Pipeline by Astellas Pharma Inc., H2 2015 49
Diffuse Large B-Cell Lymphoma - Pipeline by AstraZeneca Plc, H2 2015 50
Diffuse Large B-Cell Lymphoma - Pipeline by Aurigene Discovery Technologies Limited, H2 2015 51
Diffuse Large B-Cell Lymphoma - Pipeline by Bayer AG, H2 2015 52
Diffuse Large B-Cell Lymphoma - Pipeline by BeiGene(Beijing) Co.,Ltd, H2 2015 53
Diffuse Large B-Cell Lymphoma - Pipeline by BIND Therapeutics, Inc., H2 2015 54
Diffuse Large B-Cell Lymphoma - Pipeline by Biocon Limited, H2 2015 55
Diffuse Large B-Cell Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2015 56
Diffuse Large B-Cell Lymphoma - Pipeline by Celgene Corporation, H2 2015 57
Diffuse Large B-Cell Lymphoma - Pipeline by Cell>Point, L.L.C., H2 2015 58
Diffuse Large B-Cell Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H2 2015 59
Diffuse Large B-Cell Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H2 2015 60
Diffuse Large B-Cell Lymphoma - Pipeline by CTI BioPharma Corp., H2 2015 61
Diffuse Large B-Cell Lymphoma - Pipeline by Curis, Inc., H2 2015 62
Diffuse Large B-Cell Lymphoma - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2015 63
Diffuse Large B-Cell Lymphoma - Pipeline by Eisai Co., Ltd., H2 2015 64
Diffuse Large B-Cell Lymphoma - Pipeline by EpiZyme, Inc., H2 2015 65
Diffuse Large B-Cell Lymphoma - Pipeline by Erytech Pharma SA, H2 2015 66
Diffuse Large B-Cell Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 67
Diffuse Large B-Cell Lymphoma - Pipeline by Genentech, Inc., H2 2015 68
Diffuse Large B-Cell Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2015 69
Diffuse Large B-Cell Lymphoma - Pipeline by GlaxoSmithKline Plc, H2 2015 70
Diffuse Large B-Cell Lymphoma - Pipeline by Hutchison MediPharma Limited, H2 2015 71
Diffuse Large B-Cell Lymphoma - Pipeline by Idera Pharmaceuticals, Inc., H2 2015 72
Diffuse Large B-Cell Lymphoma - Pipeline by ImmunoGen, Inc., H2 2015 73
Diffuse Large B-Cell Lymphoma - Pipeline by Immunomedics, Inc., H2 2015 74
Diffuse Large B-Cell Lymphoma - Pipeline by Immunovaccine, Inc., H2 2015 75
Diffuse Large B-Cell Lymphoma - Pipeline by Incyte Corporation, H2 2015 76
Diffuse Large B-Cell Lymphoma - Pipeline by Inflection Biosciences Limited, H2 2015 77
Diffuse Large B-Cell Lymphoma - Pipeline by Johnson & Johnson, H2 2015 78
Diffuse Large B-Cell Lymphoma - Pipeline by Juno Therapeutics Inc., H2 2015 79
Diffuse Large B-Cell Lymphoma - Pipeline by Karus Therapeutics Limited, H2 2015 80
Diffuse Large B-Cell Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 81
Diffuse Large B-Cell Lymphoma - Pipeline by Kite Pharma, Inc., H2 2015 82
Diffuse Large B-Cell Lymphoma - Pipeline by Mabion SA, H2 2015 83
Diffuse Large B-Cell Lymphoma - Pipeline by mAbxience S.A., H2 2015 84
Diffuse Large B-Cell Lymphoma - Pipeline by MedImmune, LLC, H2 2015 85
Diffuse Large B-Cell Lymphoma - Pipeline by Medivation, Inc., H2 2015 86
Diffuse Large B-Cell Lymphoma - Pipeline by Merck & Co., Inc., H2 2015 87
Diffuse Large B-Cell Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 88
Diffuse Large B-Cell Lymphoma - Pipeline by Mirati Therapeutics Inc., H2 2015 89
Diffuse Large B-Cell Lymphoma - Pipeline by Mirna Therapeutics, Inc., H2 2015 90
Diffuse Large B-Cell Lymphoma - Pipeline by Molplex Ltd., H2 2015 91
Diffuse Large B-Cell Lymphoma - Pipeline by MorphoSys AG, H2 2015 92
Diffuse Large B-Cell Lymphoma - Pipeline by Neumedicines Inc., H2 2015 93
Diffuse Large B-Cell Lymphoma - Pipeline by Nimbus Therapeutics, LLC, H2 2015 94
Diffuse Large B-Cell Lymphoma - Pipeline by Nordic Nanovector ASA, H2 2015 95
Diffuse Large B-Cell Lymphoma - Pipeline by Novartis AG, H2 2015 96
Diffuse Large B-Cell Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 97
Diffuse Large B-Cell Lymphoma - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015 98
Diffuse Large B-Cell Lymphoma - Pipeline by Pfizer Inc., H2 2015 99
Diffuse Large B-Cell Lymphoma - Pipeline by Philogen S.p.A., H2 2015 100
Diffuse Large B-Cell Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H2 2015 101
Diffuse Large B-Cell Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H2 2015 102
Diffuse Large B-Cell Lymphoma - Pipeline by RedHill Biopharma Ltd., H2 2015 103
Diffuse Large B-Cell Lymphoma - Pipeline by Redx Pharma Plc, H2 2015 104
Diffuse Large B-Cell Lymphoma - Pipeline by Respiratorius AB, H2 2015 105
Diffuse Large B-Cell Lymphoma - Pipeline by Rhizen Pharmaceuticals S.A., H2 2015 106
Diffuse Large B-Cell Lymphoma - Pipeline by Sandoz International GmbH, H2 2015 107
Diffuse Large B-Cell Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2015 108
Diffuse Large B-Cell Lymphoma - Pipeline by Selvita SA, H2 2015 109
Diffuse Large B-Cell Lymphoma - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2015 110
Diffuse Large B-Cell Lymphoma - Pipeline by TG Therapeutics, Inc., H2 2015 111
Assessment by Monotherapy Products, H2 2015 112
Assessment by Combination Products, H2 2015 113
Number of Products by Stage and Target, H2 2015 115
Number of Products by Stage and Mechanism of Action, H2 2015 120
Number of Products by Stage and Route of Administration, H2 2015 124
Number of Products by Stage and Molecule Type, H2 2015 126
Diffuse Large B-Cell Lymphoma Therapeutics - Recent Pipeline Updates, H2 2015 395
Diffuse Large B-Cell Lymphoma - Dormant Projects, H2 2015 639
Diffuse Large B-Cell Lymphoma - Dormant Projects (Contd..1), H2 2015 640
Diffuse Large B-Cell Lymphoma - Dormant Projects (Contd..2), H2 2015 641
Diffuse Large B-Cell Lymphoma - Discontinued Products, H2 2015 642
Diffuse Large B-Cell Lymphoma - Discontinued Products (Contd..1), H2 2015 64